This study observed the effects of Notoginseng Radix et Rhizoma on the phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt)/mammalian target of rapamycin complex 1(mTORC1) signaling pathway and mitochondrial energy metabolism in the rat model of adriamycin-induced renal fibrosis with blood stasis syndrome to explore the mechanism of Notoginseng Radix et Rhizoma in protecting the kidney. Thirty male rats with adriamycin-induced renal fibrosis were randomized into model, low-, medium-, and high-dose Notoginseng Radix et Rhizoma, and positive control groups(n=6). Six clean SD male rats were selected into the normal group. The normal group and model group were administrated with normal saline, and other groups with corresponding drugs. After 8 weeks of treatment, the renal function, renal pathology, adenosine triphosphate(ATP) levels, Na~+-K~+-ATPase and Ca~(2+)-Mg~(2+)-ATPase activities, and the protein levels of ATP5B, mTORC1, 70 kDa ribosomal protein S6 kinase(P70S6K), P85, Akt, p-Akt, and SH2-containing inositol phosphatase(SHIP2) in the renal tissue were determined. Compared with the normal group, the model group showed elevated levels of blood urea nitrogen(BUN) and serum creatinine(SCr)(P<0.01). Compared with the model group, Notoginseng Radix et Rhizoma and the positive control lowered the levels of BUN and SCr, which were significant in the medium-and high-dose Noto-ginseng Radix et Rhizoma groups and the positive control group(P<0.05). Compared with the model group, Notoginseng Radix et Rhizoma and the positive control alleviated the pathological changes in the renal tissue, such as vacuolar and fibroid changes, glomerulus atrophy, cystic expansion of renal tubules, and massive infiltration of inflammatory cells. Compared with the normal group, the model group showed decreased mitochondrial ATP content and Na~+-K~+-ATPase and Ca~(2+)-Mg~(2+)-ATPase activities in the renal tissue(P<0.05), and medium-and high-dose Notoginseng Radix et Rhizoma and positive control mitigated such decreases(P<0.05). Compared with the model group, medium-and high-dose Notoginseng Radix et Rhizoma and the positive control up-regulated the protein levels of ATP5B and SHIP2 and down-regulated the protein levels of mTORC1, P70S6K, P85, Akt, and p-Akt(P<0.05 or P<0.01 or P<0.001). Notoginseng Radix et Rhizoma may exert an anti-fibrosis effect by inhibiting the activation of the PI3K/Akt/mTORC1 pathway to restore mitochondrial energy metabolism, thus protecting the kidney.

To analyze the efficacy and safety of proprietary Chinese medicines for the treatment of Lupus Nephritis (LN) based on the reticulated meta analysis. The study aim to provide evidence-based evidence for the clinical treatment of LN.The studies related to the randomized controlled studies (RCTs) on the treatment of LN with oral proprietary Chinese medicines were obtained from China National Knowledge Infrastructure (CNKI), Database for Chinese Technical Periodicals (VIP), SinoMed, Wanfang, PubMed, Web of Science, Embase and Cochrane Library databases since its inception-August 2022. Cochrane tools were used for risk bias assessment, Stata 13.0 and ADDIS 1.16.5 software were used for net evidence analysis.Results.1) 41 RCTs with 3124 L N patients were included, involving 9 types of proprietary Chinese medicines.2) The meta-analysis showed that in terms of efficacy, the top 3 Chinese patent medicine interventions were Xin Gan Bao Capsule (XGB) +western medicines (WM), Huang Kui Capsule (HK) + WM, Kun Xian Capsule (KX) + WM; in terms of reducing adverse event rate, the top 3 Chinese patent medicine interventions were Yi Shen Hua Shi Granules (YSHS) + WM, Jin Shui Bao Capsule (JSB) + WM, HK + WM; in terms of reducing 24 h urine protein, the top 3 Chinese patent medicine interventions were XGB + WM, YSHS + WM, Bai Ling Capsule (BL) + WM; in terms of reducing blood creatinine (Cr), the top 3 Chinese patent medicine interventions were Yi Shen Granules (YS) + WM, JSB + WM, KX + WM; in terms of reducing urea nitrogen (BUN), the top 3 Chinese patent medicine interventions were Shen Kang Capsule (SK) + WM, HK + WM, JSB + WM; in terms of reducing systemic lupus erythematosus disease activity index (SLEDAI) scores, the top 3 Chinese patent medicine interventions were JSB + WM, BL + WM, YSHS + WM; in terms of improving complement C3, the top 3 Chinese patent medicine interventions were HK + WM, XGB + WM, BL + WM; in terms of improving complement C4, the top 3 Chinese patent medicine interventions were KX + WM, YSHS + WM, BL + WM.Xin Gan Bao Capsule has a good efficacy in improving efficiency and the level of complement C3, lowering 24 h urine protein. Jin Shui Bao Capsule and Huang Kui Capsule have a good efficacy in treating LN. However, more multicentre, large sample and high quality RCTs are needed for validation the results.

Objective To investigate the relationship between rs1067 polymorphism of WD repeat domain(WDR)5B gene and traditional Chinese medicine(TCM)syndromes and clinical markers of ischemic stroke(IS).Methods A total of 1 567 patients with IS and healthy controls at the same time were selected.The genotyping of WDR5B gene rs1067 polymorphism was primarily per-formed with the sequenom MassARRAY SNP technology.The TCM syndromes of IS patients were classified according to the TCM Syn-drome Differentiation Diagnostic Criteria for Apoplexy.Results WDR5B gene rs1067 polymorphism was significantly associated with the occurrence of wind syndrome of IS[allelic(A/G):P=0.037;dominant(AA+GA/GG):P=0.043;additive(AA/GG):P=0.041].After adjusting for sex and age,WDR5B gene rs1067 polymorphism was still significantly associated with the risk of IS syndrome[dominant(AA+GA/GG):P=0.032;additive(AA/GG):P=0.032].After adjusting for sex and age,WDR5B gene rs1067 poly-morphism was significantly associated with postprandial 2 h plasma glucose level and high-density lipoprotein level in patients with IS(P<0.05).Conclusions WDR5B gene rs1067 polymorphism might affect the occurrence of wind syndrome of IS.WDR5B rs1067 gene polymorphism might affect postprandial 2 h plasma glucose level and high-density lipoprotein level in IS patients.

目的 基于网络药理学与分子对接技术探讨三七注射液治疗狼疮性肾炎(LN)的作用机制.方法 通过检索《中华人民共和国药典》和多个数据库查询三七注射液的主要成分三七总皂苷(PNS)的活性化学成分及其作用靶点,通过OMIM©、GeneCards©、DrugBank数据库筛选LN的相关靶点,取两者的共同靶点.使用Cytoscape 3.8.2 软件构建共同靶点及其对应活性化学成分的"活性成分-靶点"网络和共同靶点的蛋白-蛋白相互作用网络,筛选PNS治疗LN的主要活性化学成分和潜在核心靶点.对共同靶点进行基因本体论(GO)功能富集分析、京都基因与基因组百科全书(KEGG)通路富集分析,使用AutoDock 1.5.7 软件对潜在核心靶点与主要活性化学成分进行分子对接分析.结果 共得到PNS的活性化学成分 11 个及其作用靶点 250 个,LN相关靶点1 329 个,两者共同靶点49 个.PNS治疗LN的主要活性化学成分包括人参皂苷Rg1、三七皂苷R1、人参皂苷 Re、人参皂苷 Rb1 等,潜在核心靶点包括白细胞介素(IL)-6、IL-1β、IL-10、丝氨酸/苏氨酸激酶1(AKT1)、Toll样受体4(TLR4)、肿瘤坏死因子(TNF)、NFKB抑制剂α(NFKBIA)、基质金属蛋白酶9(MMP9)等.GO功能富集分析结果显示,共同靶点涉及的分子功能包括细胞因子活性等,生物过程包括炎症反应等,细胞组分包括质膜外侧等.KEGG通路富集分析得到4 条信号通路,分别为IL-17 信号通路、酪氨酸蛋白激酶/信号转导与转录激活因子(JAK/STAT)信号通路、中性粒细胞胞外陷阱信号通路、补体和凝血级联信号通路.分子对接结果显示,除三七皂苷R1 外,PNS治疗LN的主要活性化学成分与潜在核心靶点AKT1、IL-6、IL-1β、TNF具有良好的结合活性(结合能均<-4 kJ/mol).结论 PNS的人参皂苷Rg1、三七皂苷R1、人参皂苷Re、人参皂苷Rb1、人参皂苷Rg3、人参皂苷Rh1 等主要活性化学成分,可能通过IL-6、IL-1β、IL-10、AKT1、TLR4、TNF、NFKBIA、MMP9 等潜在核心靶点,作用于IL-17 信号通路、JAK/STAT信号通路、中性粒细胞胞外陷阱信号通路、补体和凝血级联信号通路等多条通路,起到治疗LN的作用.

目的 旨在探讨早期生长反应因子3基因(EGR3)rs11136094多态性与缺血性脑卒中(IS)中医证候的相关性.方法 纳入病例组774例IS患者、对照组793例健康体检人群.采用《中风病辨证诊断标准(试行)》对IS患者进行中医辨证.运用MassarraySNP基因分型实验技术进行基因分型.运用PLINK软件和SPSS19.0软件进行统计分析.结果 校正年龄、性别后,EGR3基因rs11136094多态性与IS风证的发生风险显著相关﹝加性模型:OR(95％CI)=0.82(0.68～0.99),P=0.041;隐性模型:OR(95％CI)=0.67(0.49～0.91),P=0.010;EGR3基因rs11136094多态性与IS风证评分的关联具有统计学意义﹝隐性模型:β(95％CI)=-0.81(-1.49～-0.13),P=0.019﹞;rs11136094多态性与IS风证患者的血小板(PLT)水平显著相关﹝隐性模型:β=(95％CI)=24.68(4.37～44.99),P=0.018﹞.结论 EGR3基因rs11136094遗传多态性可能影响IS风证的发生发展.

目的 观察眩晕汤联合甲磺酸倍他司汀片治疗良性阵发性位置性眩晕(BPPV)手法复位后残留眩晕的临床效果.方法 选择90例BPPV手法复位后残留眩晕的患者,将其随机分成3组,每组30例.A组给予甲磺酸倍他司汀片治疗,B组给予眩晕汤治疗,C组给予眩晕汤联合甲磺酸倍他司汀片治疗.3组患者均连续治疗14d.观察3组患者治疗3d、7d后的临床疗效,治疗前1d、治疗7d和14d后的眩晕障碍量表(DHI)评分,以及治疗后1个月、3个月、6个月的复发情况.结果 治疗3 d后,B组和C组的临床疗效均优于A组;治疗7 d后,C组的临床疗效优于A组和B组,而B组优于A组(均P<0.05).治疗7 d、14 d后,DHI得分均A组>B组>C组(均P<0.05).治疗后1个月、3个月及6个月,C组的复发率均低于A组和B组(均P<0.05).结论 眩晕汤联合甲磺酸倍他司汀片治疗BPPV手法复位后残留眩晕的临床效果显著,与单一药物治疗相比,其可更好地改善患者的头晕症状,降低复发率,值得临床推广.

目的 研究旨在探讨中国汉族人群中lncRNA SH3BP5-AS1多态性rs11713836与缺血性中风(ischemic stroke,IS)遗传易感性及中医证候的关系.方法 研究包括774例IS患者和793例对照组.采用Massarray SNP基因分型方法进行基因分型.采用《中风病中医辨证诊断标准》量表对IS患者进行中医证候鉴定.所有统计分析采用SPSS 17.0统计软件进行.结果 在隐性模型下,lncRNA SH3BP5-AS1多态性rs11713836与缺血性中风血瘀证显著相关[OR(95％CI)=0.52(0.29-0.93),P=0.028],在校正了包括性别和年龄在内的协变量后,结果依然有统计学意义;而rs11713836与缺血性中风易感性及风、痰、火热、气虚证等中医证候易感性无相关性.此外,rs11713836与血清APO-B[隐性模型:OR(95％CI)=0.09(0.02-0.17),P=0.032]、VLDL[加性模型:OR(95％CI)=0.09(0.04-0.14),P＜0.001;显性模型:OR(95％CI)=0.09(0.02-0.16),P=0.011;隐性模型:OR(95％CI)=0.19(0.09-0.30),P＜0.001]、TG[加性模型:OR(95％CI)=0.15(0.05-0.24),P=0.003;显性模型:OR(95％CI)=0.14(0.01-0.27),P=0.041;隐性模型:OR(95％CI)=0.31(0.11-0.50),P=0.003]、FIB[显性模型:OR(95％CI)=0.20(0.04-0.35),P=0.012]显著相关,调整性别年龄后以上关联依然有统计学意义.结论 lncRNA SH3BP5-AS1多态性rs11713836可能影响缺血性中风血瘀证的发生,有望作为缺血性中风血瘀证的生物标志物与潜在治疗靶点,并且可能影响缺血性中风患者的血脂代谢和凝血功能.